# Evaheart

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/evaheart

- Industry: Medical Devices & Equipment
- Headquarters: Chongqing, China
- Total disclosed funding: $100M
- Latest round: Series A (Mar 9, 2023)
- Investors on record: 3

## About

Established in 2014 and based in Chognqing, China, Evaheart is a medical device developer that focuses on the research and development of artificial heart. The company was acquired by Vivo Capital in June 2021.  Evaheart has cooperated with Tokyo Women's Medical University and Waseda University. The artificial heart product has been approved by the Drug Enforcement Administration. In March 2023, the company raised approximately USD 100 million in series A funding led by new investor Sinovac Biotech Co. Ltd., with participation from other new investor Taiping Innovation Investment Management and returning investor Vivo Capital.

The company focuses on the research and development of artificial heart, providing treatment before heart transplantation or heart function restore. Its artificial heart, named as Evaheart, uses the latest liquid suspension technology to achieve a physiologically pulsating blood flow imitation. Evaheart also can increase ejection during systole and decrease ejection during diastole, which maintains a 20-30 mmHg pulse pressure difference and produces pulsatile blood flow. The company also provides patients with a full life-cycle solution from prevention, diagnosis, monitoring, treatment and end-stage assistance.

## Funding rounds

- Series A, Mar 9, 2023, $100M — Vivo Capital, Sinovac Biotech Co. Ltd., Taiping Innovation Investment Management

## Investors

- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A
- Sinovac Biotech Co. Ltd. — Series A
- Taiping Innovation Investment Management — Series A